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Effects of the Ser326Cys polymorphism in the DNA repair OGG1 gene on cancer, 1 
cardiovascular and all-cause mortality in the PREDIMED study: Modulation by the 2 
Mediterranean diet 3 
 4 
 5 
RESEARCH SNAPSHOT 6 
Research Question: Is the lower DNA-repair capacity genotype (homozygous individuals for the 7 
Cys326 allele) in the OGG1-rs1052133 (Ser326Cys) polymorphism associated with cancer 8 
mortality or other causes and are these associations modulated by Mediterranean diet (MedDiet) 9 
or vegetable intake? 10 
Key findings: In the PREDIMED dietary intervention trial including 7,170 participants, the 11 
Cys326Cys-OGG1 genotype was associated with higher total mortality, mainly cardiovascular 12 
mortality. For cardiovascular and total mortality, no statistically significant interactions were 13 
found with the MedDiet intervention. However, when vegetable intake was considered, 14 
significant interactions decreasing the risk for cardiovascular mortality in homozygous 15 
individuals with higher intake were detected. 16 
 17 
 18 
 19 
ABSTRACT 20 
 21 
Background: Oxidatively induced DNA damage, an important factor in cancer etiology, is 22 
repaired by oxyguanine glycosylase 1 (OGG1). The lower repair capacity genotype (homozygote 23 
Cys326Cys) in the OGG1-rs1052133 (Ser326Cys) polymorphism has been associated with 24 
cancer risk. However, no information is available in relation to cancer mortality, other causes of 25 
*Manuscript
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death and modulation by diet. 26 
Objective: Our aim was to evaluate the association of the OGG1-rs1052133 with total, cancer 27 
and cardiovascular (CVD) mortality and to analyze its modulation by the Mediterranean diet 28 
(MedDiet), focusing especially on total vegetable intake as one of the main characteristics of this 29 
diet. 30 
Design: PREDIMED is a randomized, controlled trial conducted in Spain from 2003 to 2010. 31 
Participants/setting: Study participants (n=7,170) were at high risk for CVD and aged 55-80 32 
years. 33 
Intervention: Participants were randomly allocated to two groups with a MedDiet intervention 34 
or to a control diet. 35 
Main Outcome measures: Main outcomes were all-cause, cancer and CVD mortality after a 36 
median follow-up of 4.8 years. 37 
Statistical analyses: Multivariable-adjusted Cox regression models were fitted. 38 
Results: 318 deaths were detected (cancer=127, CVD=81 and others=110). Cys326Cys 39 
individuals (prevalence 4.2%) presented higher total mortality rates than Ser326-carriers 40 
(P=0.009). The multivariable-adjusted Hazard Ratio (HR) for Cys326Cys versus Ser326-carriers 41 
was 1.69 (95%CI:1.09-2.62); P=0.018. This association was greater for CVD mortality 42 
(P=0.001). No relationship was detected for cancer mortality in the whole population (HR:1.07; 43 
95%CI:0.47-2.45; P=0.867), but a significant age interaction (P=0.048) was observed as 44 
Cys326Cys was associated with cancer mortality in participants <66.5 years (P=0.029). 45 
Recessive effects limited our ability to investigate Cys326Cys*diet interactions for cancer 46 
mortality. No statistically significant interactions for total or CVD mortality were found for the 47 
MedDiet intervention. However, significant protective interactions for CVD mortality were found 48 
for vegetable intake (HR-interaction per standard deviation: 0.42;95%CI:0.18-0.98, P=0.046). 49 
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Conclusions: In this population, the Cys326Cys-OGG1 genotype was associated with all-cause 50 
mortality, mainly CVD instead of cancer mortality. Additional studies are needed to provide 51 
further evidence on its dietary modulation. 52 
 53 
 54 
  55 
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INTRODUCTION 56 
DNA molecules are exposed to the attack of DNA-damaging agents
1
, among them 57 
reactive oxygen species (ROS)
2
. Oxidatively induced DNA damage can be both mutagenic and 58 
cytotoxic
3
 and has been implicated in the etiology of cancer
4
, neurodegenerative diseases
5
 and 59 
overall aging
6
. Hydroxyl radicals preferentially react with the C8 atom of purines in DNA to 60 
generate 8-oxo-7,8-dihydroguanine (8-oxoG), 8-oxo-7,8-dihydroadenine (8-oxoA) and 61 
formamidopyrimidines (Fapy)
7
. The accumulation of unrepaired DNA damage can cause genetic 62 
instability and has deleterious effects on cell function
8
. 8-oxoG is a critical mutagenic lesion 63 
because of its propensity to mispair with A during DNA replication
7
. Repair of oxidatively 64 
damaged bases occurs primarily via the DNA base excision repair (BER) pathway
2
. In the first 65 
step of this type of repair, damaged bases are removed from DNA by DNA glycosylases
9
. The 66 
oxyguanine glycosylase 1 (OGG1) is the human DNA glycosylase responsible for removal of the 67 
highly mutagenic 8-oxoG from DNA
7
. The OGG1 gene is located in chromosome 3p26.2 and 68 
this region has frequently been detected as deleted in various tumors suggesting the loss of this 69 
gene as a possible contributor to carcinogenesis
7,10-13
. 70 
The most studied polymorphism in the human OGG1 gene is the rs1052133 (Ser326Cys), 71 
a C to G transversion at nucleotide 1245 in exon 7, leading to a serine to cysteine substitution at 72 
residue 326 
14
. This variant is functional and it has been shown that the Cys326 protein has 73 
weaker 8-hydroxyguanine-repair capacity than the Ser326 protein
15-17
. The deactivation of the 74 
OGG1 gene or the presence of a less active variant such as the Cys326 may lead to a higher risk 75 
of cancer and oxidation-related pathologies
7,13,18
. Consequently, this polymorphism has been 76 
analyzed as a risk factor in several cancers
19-25
 (i.e., breast, prostate, lung, colorectal, aero 77 
digestive, gastric, bladder). The results of meta-analyses for each location are heterogeneous
21-25
, 78 
but where there is more consensus is in the significant association of the Ser326Cys 79 
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polymorphism with greater overall risk of cancer when the different locations are pooled
26,27
. 80 
Thus, Zou et al
26
 in a meta-analysis including 152 case-control studies, concluded that the Cys 81 
variant was strongly associated with higher cancer risk. Interestingly, the cancer risk was higher 82 
in homozygous individuals for the Cys variant, suggesting a recessive pattern. This observation 83 
agrees with several functional studies showing that only homozygous carriers of the Cys allele 84 
showed a significantly lower DNA repair activity compared to Ser326Ser
16,18
. A potential source 85 
of the observed heterogeneity found among studies may be the exposure to different 86 
environmental factors
28-31
 (i.e. mainly vegetable intake and other dietary factors). 87 
 The Ser326Cys OGG1 polymorphism has also been associated with a greater risk of 88 
atherosclerosis
32,33
 and incidence of cardiovascular diseases
34,35
, although there have been very 89 
few studies that have specifically focused on cardiovascular phenotypes. 90 
 Whereas many studies have analyzed the influence of the OGG1 Ser326Cys 91 
polymorphism on cancer risk, few have analyzed its influence on mortality due to cancer. 92 
Moreover, if the OGG1 gene also makes an important contribution to other pathologies, such as 93 
cardiovascular diseases, there is compelling interest in knowing whether, in the same cohort, this 94 
gene has a greater influence on mortality due to cancer or on mortality due to cardiovascular 95 
disease. The aims were, first, to analyze the influence of the OGG1 Ser326Cys polymorphism on 96 
cancer mortality, cardiovascular mortality and on total mortality in a high cardiovascular risk 97 
Mediterranean population and second to investigate the possible modulation by diet by analyzing 98 
the Mediterranean diet (MedDiet) intervention as well as focusing on total vegetable intake as 99 
one of the main characteristics of the MedDiet. 100 
 101 
METHODS 102 
The present study was conducted within the framework of the PREDIMED trial, the 103 
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design of which has been described in detail elsewhere
36
. Briefly, the PREDIMED study is a 104 
multicenter, randomized and controlled clinical trial aimed at assessing the effects of the 105 
MedDiet on the primary cardiovascular prevention
37
. This study was registered at controlled-106 
trials.com (http://www.controlledtrials.com/ISRCTN35739639). Here, 7,170 participants (from 107 
a total of 7,447) were included from whom DNA was isolated and the OGG1-rs1052133 108 
(Ser326Cys) polymorphism determined. Briefly, from October 2003 to June 2009 physicians in 109 
Primary Care Centers located in several Spanish regions selected high-cardiovascular risk 110 
participants. Eligible participants were community-dwelling adults at high cardiovascular risk 111 
(55-80 years for men; 60-80 years for women) who met at least one of two criteria: diabetes or 3 112 
or more cardiovascular risk factors (hypertension, dyslipidemia, overweight or obesity, current 113 
smoking, or a family history of premature coronary heart disease)
36
. Exclusion criteria were the 114 
presence of any severe chronic illness, previous history of cardiovascular diseases, alcohol or 115 
drug abuse, and history of allergy or intolerance to olive oil or nuts. Hence, individuals with 116 
incident cancer undergoing treatment were excluded, but individuals that reported having had 117 
some form of cancer in previous years but who had no clinical signs of cancer at the time of 118 
enrollment were not excluded. 119 
Participants were randomly assigned to these interventions: a MedDiet (2 groups, one 120 
supplemented with extra-virgin olive oil and the other with nuts) and a control group (advised to 121 
follow a low-fat diet). Randomization was performed by means of a computer-generated 122 
random-number sequence (randomly assigned in a 1:1:1 ratio to one of three groups). 123 
Participants assigned to both MedDiet groups received intensive training to follow the MedDiet 124 
and allotments of either extra-virgin olive oil (1L/week) or mixed nuts (30 g/d) throughout the 125 
entire study time period, whereas those assigned to the control diet were instructed to reduce the 126 
intake of all types of fat
37
. Because both MedDiet intervention groups had a similar effect 
37
, 127 
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these groups were pooled and analyzed together. The primary end point of the PREDIMED trial 128 
was cardiovascular disease incidence, including a composite endpoint comprised of myocardial 129 
infarction incidence, stroke incidence and cardiovascular death. Total and cause-specific 130 
mortality were considered as secondary endpoints. In this study, total and cause-specific 131 
mortality will be analyzed, focusing on mortality due to cancer and cardiovascular events. 132 
The Institutional Review Board of each participating center approved the study protocol, 133 
and all participants provided written informed consent. The trial was stopped following the 134 
statistical analysis of data obtained up to December 2010, due to early evidence of the benefit of 135 
the MedDiet on the prevention of major cardiovascular events
37
. This study is based on the data 136 
obtained from this follow-up period (median follow-up of 4.8 years) with dietary intervention 137 
throughout the entire study time period. 138 
 139 
Demographic, clinical, anthropometric and dietary measurements 140 
The baseline examination included assessment of standard cardiovascular risk factors, 141 
medication use, socio-demographic factors and lifestyle variables by validated 142 
questionnaires
36,38,39
. Adherence to the MedDiet was measured by a validated 14-item 143 
questionnaire
38
. Food and beverage consumption was reported using a validated 137-item 144 
semiquantitative food-frequency questionnaire (FFQ)
39
. Dietary data from the FFQ were 145 
obtained for 7,122 participants. Weight and height were measured with calibrated manual or 146 
digital scales and a wall-mounted stadiometer, respectively
36
. Body mass index (BMI) was 147 
calculated as kg/m
2
. 148 
 149 
Biochemical determinations, DNA extraction and genotyping 150 
Fasting glucose and lipids were measured as previously described
40
. Biochemical 151 
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measures were available for nearly 7000 participants at baseline. Genomic DNA was extracted 152 
from buffy-coat and the OGG1-rs1052133 (Ser326Cys) polymorphism was genotyped in the 153 
whole cohort with DNA available on a 7900HT Sequence Detection System (Applied 154 
Biosystems, FosterCity, CA, USA) using a fluorescent allelic discrimination TaqManTM assay. 155 
Valid genotype results for 7,170 participants were obtained. Genotype frequencies did not 156 
deviate from Hardy-Weinberg equilibrium expectations (P=0.882). 157 
 158 
Outcomes and Follow-up 159 
The end points of interest in the present analysis were cancer mortality, cardiovascular 160 
mortality and all-cause mortality after the follow-up period. We used the following 4 sources of 161 
information to identify deaths: contacts with families of participants, contacts with general 162 
practitioners who were responsible for the routine clinical care of participants, yearly 163 
consultation of the National Death Index, and a comprehensive yearly review of medical records 164 
of all participants by medical doctors who were blinded with respect to the group allocation and 165 
all nutritional information. All medical records related to endpoints were examined by the Event 166 
Adjudication Committee, whose members were unaware of the dietary information
37
. Only 167 
endpoints that were confirmed by the Event Adjudication Committee were included in the 168 
analyses. In this follow-up, all deaths detected in the 7,170 patients analyzed (those that had 169 
genotype OGG1 data), and that occurred between 1 October 2003 and 1 December 2010 were 170 
included: Total deaths (n=318), per total cancer (n=127) and per cardiovascular diseases (n=81). 171 
 172 
Statistical analyses 173 
The OGG1-rs1052133 polymorphism was first tested as codominant with the three 174 
genotypes considered and taking into account the Ser326Ser genotype as reference. Given that, in 175 
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the total and cause-specific association models, the effects of the Ser326Ser and Ser326Cys 176 
genotypes were similar and no statistically significant differences were found between them, 177 
carriers of the Ser326 allele were grouped together and compared to those of Cys326Cys 178 
participants (recessive model). Triglycerides were log-transformed for statistical analyses. 179 
Vegetable intake was standardized for further Cox regression analyses. ANOVA tests were used 180 
to compare means of continuous variables by the OGG1 polymorphism and cause of death. The 181 
association between the OGG1-rs1052133 polymorphism and the different causes of death were 182 
analyzed by means of the Chi Square test, using both codominant and recessive models. 183 
To examine the longitudinal association between the OGG1-rs1052133 polymorphism 184 
and mortality (separated models for all-cause, cancer and cardiovascular mortality) in the 4.8 185 
years median follow-up, Cox regression models were used with length of follow-up as the 186 
primary time variable. The exposure time was calculated as the time between randomization and 187 
the date at death, the date when the last interview was completed on 1 December 2010, 188 
whichever came first. Firstly, the mortality rate for the 3 genotypes and fitted codominant models 189 
were estimated. After having checked that there were no significant differences between the 190 
estimates of genotypes Ser326Ser and Ser326Cys, both genotypes were grouped together as Ser-191 
carriers. This group was used as the category of reference and homozygous Cys326Cys were 192 
compared with it using a recessive model. Hazard Ratios (HRs) with 95% CIs for the OGG1-193 
rs1052133 genotypes were estimated. Models were sequentially adjusted for covariates as 194 
indicted. Model 1 was adjusted for age, sex, field center and dietary intervention group (three 195 
groups). Model 2 was additionally adjusted for type-2 diabetes, BMI, and self-reported personal 196 
history of a previously diagnosed cancer at baseline. Model 3 was additionally adjusted for 197 
alcohol consumption, smoking, physical activity, hypertension, dyslipidemia, medications (lipid-198 
lowering, hypoglycemic, and antihypertensive drugs) adherence to MedDiet and total energy 199 
10 
 
intake in the models analyzing diet. 200 
 Also evaluated was the heterogeneity of the OGG1-rs1052133 associations with mortality 201 
by age groups. Two age groups were considered, taking into account the median age of the 202 
population (66.5 years). Formal tests for the interaction between the OGG1 polymorphism and 203 
age group in determining mortality (total, cancer and cardiovascular deaths) were carried out by 204 
analyzing the product term of these variables in the corresponding hierarchical Cox regression 205 
model. Testing this interaction in a Cox regression model estimates the departure from 206 
multiplicativity instead of the departure from additivity
41,42
. Stratified analyses of both age 207 
groups were carried out. Finally, the modulation by Mediterranean diet of the associations 208 
between the OGG1-rs1052133 polymorphism and CVD mortality and total mortality were 209 
evaluated. First of all, the randomized and controlled clinical trial design (MedDiet intervention 210 
compared with the control diet) was used. Analyses were based on the intent-to-treat principle. 211 
Models were sequentially adjusted for covariates as previously indicated (model 1, model 2 and 212 
model 3). Multiplicative tests for the interaction between the OGG1 polymorphism and MedDiet 213 
intervention in determining mortality (total and cardiovascular mortality) were carried out in the 214 
multivariable adjusted Cox regression models. Stratified analyses by dietary intervention groups 215 
were undertaken. 216 
 In addition to the modulation by MedDiet intervention, as secondary analysis, the 217 
influence of total vegetable intake at baseline (observational cohort design) was investigated, as 218 
vegetables are a main food of the MedDiet previously reported to statistically interact with the 219 
OGG1-rs1052133 polymorphism
28
. Vegetable intake was used as categorical (dichotomously, 220 
using the consumption median of the population as the cut-off point) and as a continuous variable 221 
(in grams/day). For the continuous variable, the HRs of mortality per standard deviation (SD) of 222 
vegetable intake were calculated. Multivariable Cox regression models were fitted and interaction 223 
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terms analyzed. Taking into account the relevance of age in mortality, dietary interactions by age 224 
groups were also explored. 225 
Kaplan-Meier survival curves were plotted to estimate the probability of remaining free of 226 
mortality (total or causes) during follow-up. Statistical analyses were performed with the IBM 227 
SPSS Statistics version 24.0
43
. All tests were 2-tailed, and P < 0.05 was considered statistically 228 
significant. 229 
 230 
RESULTS 231 
Descriptive characteristics of participants and causes of death by OGG1-rs1052133 232 
(Ser326Cys) genotypes 233 
Table 1 presents demographic, clinical and lifestyle characteristics at baseline of the 234 
7,170 PREDIMED participants according to their genotype in the OGG1-rs1052133 (Ser326Cys) 235 
polymorphism. Overall, there were no differences among genotypes in the main characteristics 236 
analyzed. The only statistically significant differences were observed in BMI and triglycerides. 237 
The OGG1 genotypes were equally distributed into the three dietary intervention groups. 238 
Following 4.8 years of median follow-up, 318 deaths were confirmed, of which the majority were 239 
from cancer (n=127), followed by cardiovascular diseases (n=81) and other causes (n=110 240 
deaths). Table 2 presents the baseline characteristics of the participants depending on whether 241 
participants were still alive or had died after 4.8 years of median follow-up. Within the mortality 242 
group, the cause of death was also reported. The mean age at baseline of the individuals still 243 
living was lower than that of the deceased. Among the deceased, the mean age was lower in those 244 
who died from cancer than from cardiovascular diseases. Although, in this study, individuals with 245 
a recently diagnosed cancer were not included, there were 184 participants with a prior diagnosis 246 
of cancer (in any location), presumably cancer-free at enrollment according to self-reports. 247 
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Greater mortality due to cancer was detected in individuals who had previously been diagnosed 248 
with cancer compared to those who had not (P<0.001). The effect was high (HR: 5.91; 95%CI: 249 
3.52-9.92; P<0.001, for cancer mortality and HR: 3.13; 95%CI: 2.04-4.80; P<0.001 for total 250 
mortality, in model 1), so this variable was included as an adjustment variable in the later 251 
multivariable Cox regression models. Table 2 also presents the frequencies of the OGG1-252 
rs1052133 polymorphism according to vital status and cause of death. In the model in which the 253 
three genotypes were analyzed separately, genotypes Ser326Ser and Ser326Cys were distributed 254 
equally among the different causes of death (P>0.05). However, the Cys326Cys genotype 255 
differed in some causes of death (P<0.05) and when comparing total mortality. In the recessive 256 
model, the Cys326Cys genotype was associated with all-cause mortality (P=0.006), being more 257 
frequent in mortality cases than in non-cases, while the highest frequency of the Cys326Cys 258 
genotype occurred in cardiovascular diseases. The detection of this recessive effect will limit the 259 
statistical power of subsequent comparisons. 260 
 261 
Multivariable-adjusted associations of the OGG1-rs1052133 polymorphism with total, 262 
cancer and cardiovascular mortality 263 
Table 3 presents mortality rates, HRs and 95% CI for the OGG1 genotypes for total, 264 
cancer and cardiovascular mortality after 4.8 years of median follow-up (maximum follow-up of 265 
7.4 years) obtained in the multivariable-adjusted Cox-regression models (model 1, model 2 and 266 
model 3). For all-cause mortality, higher total mortality rates in homozygous Cys326Cys were 267 
detected in comparison with the other genotypes (Ser-carriers): HR for total mortality in 268 
Cys326Cys participants: 1.77; 95% CI: 1.16-2.71; P=0.009, in the minimally adjusted model 1 269 
(adjusted for sex, age, field center and dietary intervention group). After additional multivariable 270 
adjustment in model 3 (including BMI, diabetes, self-reported history of cancer, smoking, 271 
13 
 
drinking, physical activity, adherence to the MedDiet and medications), this association remained 272 
statistically significant (HR: 1.69; 95% CI:1.09-2.62; P=0.018). On analyzing the specific causes 273 
of death separately, a strong association was found between the OGG1 polymorphism and 274 
cardiovascular mortality (HR: 3.31; 95% CI: 1.68-6.53; P=0.001 for Cys363Cys participants in 275 
comparison with Ser-carriers in the multivariable adjusted model 3). However, on studying the 276 
overall association of the OGG- rs1052133 polymorphism with mortality from cancer, even 277 
though in this population there were more deaths from cancer than from cardiovascular diseases 278 
(n=127 compared to n=81, respectively), no statistically significant association was detected in 279 
the case of cancer. Also using a recessive model, the HR for cancer mortality in Cys326Cys 280 
individuals in comparison with Ser-carriers was 1.07; 95%CI: 0.47-2.45; P=0.867. Comparing 281 
the Cys326Cys with the Ser326Ser, the results of no association were similar. Figure 1 shows 282 
Kaplan Meier curves of cumulative mortality–free survival for total mortality (A) cardiovascular 283 
(B) and cancer mortality (C) by the three OGG1-rs1052133 genotypes in the whole population. 284 
Bearing in mind that mortality from cancer occurs in younger individuals, whereas mortality 285 
from cardiovascular diseases occurs in older individuals, the influence of the age group (two 286 
groups according to the median of age at baseline) on the associations of the OGG1 287 
polymorphism was analyzed (Table 4). It was observed that there was heterogeneity by age in 288 
the association of the OGG1- rs1052133 polymorphism with cancer mortality, in such a way that 289 
in younger individuals (less than 66.5 years at baseline), the Cys326Cys genotype was 290 
significantly associated (Table 4 and Figure 1D) with higher cancer mortality (HR: 3.27; 95%CI: 291 
1.13-9.47; P=0.029 for Cy362Cys participants compared to Ser-carriers in model 3). 292 
Nevertheless, in those 66.5 years or older, no significant association was detected (P=0.285). One 293 
important limitation in this estimation is the small number of cases of fatal cancer in Cys326Cys 294 
homozygous individuals. However, despite this limitation of sample size, a statistically 295 
14 
 
significant interaction term between age group and the OGG1 polymorphism on cancer mortality 296 
(P-interaction=0.048 in model 3) was obtained. Cancer deaths (n=41) in participants <66.5 years 297 
at baseline were as follows: lung (26.8%), pancreatic-biliary (12.2%), colorectal (9.8%), gastric 298 
(7.3%), prostate (7.3%), liver (2.4%), ovary-endometrial (2.4%) and other locations (31.7%). 299 
For cardiovascular mortality, an opposite effect was observed. Most of the mortality and 300 
the greatest association with the OGG1 polymorphism occurred in the older age group (>=66.5 301 
years). However, on testing the interaction per age, no statistically significant value (P=0.234 in 302 
model 3) was detected, as although the risk is lower in the younger group, the association goes in 303 
the same direction. Neither was a statistically significant heterogeneity of the association of the 304 
polymorphism by age group with total mortality found (P-interaction=0.570 in model 3). 305 
 306 
Effect of the MedDiet intervention on the association between the OGG1-rs1052133 307 
polymorphism and mortality 308 
The influence that diet had on modulating the Cys326Cys genotype association with 309 
greater mortality (total and cardiovascular) was analyzed. Modulation by diet in mortality due to 310 
cancer was not analyzed owing to the small number of Cys326Cys participants dying from cancer 311 
(n=6) and, besides, an additional interaction per age group had been detected that presents 312 
heterogeneity and limits statistical power still further (n=4 cancer deaths in Cys326Cys 313 
participants aged <66.5 years at baseline). Table 5 presents the results of the modulation of the 314 
Cys326Cys genotype associations with total mortality and per cardiovascular diseases depending 315 
on the intervention with MedDiet (both groups considered jointly) or the control diet. For total 316 
mortality, no statistically significant interaction between the genotype and intervention with 317 
MedDiet (P-interaction=0.752, in model 3) was found. Likewise, for cardiovascular mortality, 318 
the interaction term between intervention with the MedDiet and the OGG1 polymorphism did not 319 
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reach statistical significance (P-interaction=0.181 in model 1 and P-interaction=0.200 in model 320 
3). 321 
In subgroup analysis by age we found that for total mortality the interaction term between 322 
the OGG1 polymorphism and MedDiet intervention reached statistical significance in 323 
participants aged ≥ 66.5 years in model 1 (P-interaction=0.049). However, in model 3 after 324 
additional multivariable adjustment (HR for Cys326Cys in the MedDiet group: 1.30; 95%CI: 325 
0.65-2.60; P=0.451 versus HR for Cys326Cys in the control group: 2.99; 95%CI:1.34-6.67; 326 
P=0.008, in the stratified analysis), the statistical significance of the interaction term for this 327 
comparison was lost (P-interaction=0.112). Likewise, for cardiovascular mortality, the interaction 328 
terms in this group did not reach statistical significance (P-interaction=0.082 in model 1 and 329 
P=0.086 in model 3). 330 
 331 
Effect of vegetable intake on the association between the OGG1-rs1052133 polymorphism 332 
and mortality 333 
Finally, vegetable intake at baseline (Table 6) was focused on. No statistically significant 334 
interactions between vegetable intake and the OGG1-rs1055133 polymorphism in determining 335 
total mortality were found (P-interaction=0.491 for categorical and P=0.367 for continuous 336 
variables in model 3). However, when cardiovascular mortality was analyzed, a statistically 337 
significant interaction term between vegetable intake (as continuous variable) and the OGG1 338 
polymorphism in determining cardiovascular mortality in the whole population (P-339 
interaction=0.035 in model 1, which remained statistically significant in model 3, P-340 
interaction=0.046) was detected. According to this interaction, a high vegetable intake decreased 341 
the risk of cardiovascular mortality more in Cys326Cys individuals than in Ser-carriers: HR-342 
interaction: 0.42; 95%CI: 0.18-0.98, per 1 SD (150 g/d) of vegetable intake. When vegetable 343 
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intake was analyzed as dichotomous (2 groups according to the median intake of the population), 344 
it was observed that the Cys326Cys genotype was associated with higher cardiovascular 345 
mortality in comparison with Ser-carriers (P<0.001 in model 3), in participants having a low 346 
vegetable intake (<314 g/d). However, Cys326Cys participants having a high vegetable intake 347 
(>=314 grams/d) did not present a statistically significant higher risk of cardiovascular mortality 348 
in comparison with Ser-carriers (P=0.671). Although the P-value for the corresponding 349 
interaction term did not reach the statistical significance (P=0.101, in model 3) for the 350 
dichotomous variable of vegetable intake, due to very small number of Cys326Cys participants, 351 
this observation was supported by the statistical significance of the interaction term between the 352 
OGG1 genotype and vegetable intake as continuous variable. 353 
In the subgroup analysis in participants aged ≥ 66.5 years, a statistically significant 354 
interaction between vegetable intake (as continuous variable) and the OGG1 polymorphism in 355 
determining total mortality (HR-interaction: 0.49; 95%CI: 0.25-0.96; P=0.037 per SD, in model 356 
3) was obtained. Also in participants aged ≥ 66.5 years, the interaction term between vegetable 357 
intake (as continuous) and the OGG1 polymorphism was statistically significant for 358 
cardiovascular mortality (HR-interaction: 0.30; 95%CI: 0.11-0.83; P=0.021, per SD, in model 3). 359 
 360 
DISCUSSION 361 
In this study the influence of the OGG1-rs1052133 (Ser326Cys) polymorphism on total 362 
and cause-specific mortality, including cancer and cardiovascular mortality, has been 363 
longitudinally investigated in a cohort of older participants in the PREDIMED study. This 364 
polymorphism, in which the Cys326Cys genotype has been associated with a lower damage 365 
repair capacity in DNA
15-17
, has also been associated with a higher risk of cancer and other 366 
diseases related to DNA repair in many studies
7,18-27
. However, no previous study has jointly 367 
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analyzed the impact of this polymorphism on total mortality and in a comparative manner on 368 
cancer and cardiovascular mortality in the same population. In this sense, the current study results 369 
on the contribution of the OGG1-rs1052133 genotypes to the mortality rate per 1,000 (person-370 
years of follow-up) as well as to the mortality risk, are novel. 371 
Overall, a statistically significant association of the OGG1-rs1052133 (Ser326Cys) 372 
polymorphism with all-cause mortality has been found; the mortality risk of Cys326Cys 373 
participants being 1.69 times higher than that of the other genotypes (recessive effects). This 374 
association was stronger for cardiovascular mortality, whereas for cancer mortality no association 375 
was detected for the OGG1-rs1052133 polymorphism in the whole population. The association 376 
with cancer was only statistically significant in participants aged less than 66.5 years at baseline. 377 
The observation of recessive effects limited the statistical power of our subsequent gene-diet 378 
interaction analyses
44
. Moreover, the small number of Cys326Cys participants may have led to an 379 
overestimation of effect size in some associations, in the so-called winner's curse
45
. This term 380 
refers to the phenomenon by which studies that first find evidence of an effect often provide 381 
inflated estimates of the size of that effect
45
. Effect inflation is worse for small, low-powered 382 
studies. However, despite some inflation of the effects, a true association effect can be present in 383 
large, well-designed prospective studies
46,47
. Therefore, it can be assumed that some associations 384 
found in the present study, mainly those obtained in subgroup analyses, may be overestimated 385 
due to the low number of Cys326Cys carriers. Supporting a true association, the current study’s  386 
results are consistent with dozens of previous studies in animal models that show harmful health 387 
effects associated with a reduced DNA repair capacity of the variants in the OGG1 gene
7,48-52
 388 
They are also consistent with work in humans that associate the Cys326 variant with a higher risk 389 
of cancer
11-27 
as well as other diseases
2,33,53-55
. However, as far as we know, no previous study has 390 
estimated the influence of this polymorphism on total mortality. One of the factors that can help 391 
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explain the strong associations found between the OGG- rs1052133 polymorphism and mortality 392 
is that a high cardiovascular risk population is being analyzed. In a subsample of this 393 
population
56
, higher levels of the DNA- damaged product 8-oxo-7′8′-dihydro-2′-deoxyguanosine 394 
(8-oxo-dG) were previously detected in nucleated blood cells in comparison with participants 395 
from the general population (not at high cardiovascular risk) paired by age and sex (5.61±1.17 in 396 
PREDIMED participants versus 3.71±0.65 in non-high cardiovascular risk participants, 397 
expressed as 8-oxo-dG/10
6
dG; P<0.001). This is relevant considering the reports on the impaired 398 
DNA repair capacity of the Cys326Cys variant being enhanced under conditions of oxidative 399 
stress
17
, largely increasing the risk of oxidative patothologies
18
. 400 
Although several studies have analyzed the influence of the OGG1-rs1052133 on cancer 401 
incidence or prevalence
19-27
, no previous study at the population level has analyzed the 402 
association of such polymorphism with cancer mortality. Some studies have analyzed the 403 
influence of the OGG1-rs1052133 polymorphism on the survival or prognosis of selected groups 404 
of patients receiving cancer treatment
57, 58
, but there are no estimates of mortality rates in a 405 
general population cohort. Although in our cohort at high cardiovascular risk deaths from cancer 406 
outnumbered those from cardiovascular disease, no association between the Cys326Cys genotype 407 
and cancer mortality was observed in the whole population. However, a strong association was 408 
detected between the Cys326Cys risk genotype and cardiovascular mortality. Although in 409 
comparison to studies that have examined the possible association between the OGG1-rs1052133 410 
polymorphism and cancer
18-31
, very few have examined its association with cardiovascular 411 
disease
33-35,54
, studies in animal models on OGG1 function strongly support this 412 
association
32,59,60
. Thus, in a study by Tumurkhuu et al
32
 in Ogg1(-/-) mice, the authors observed 413 
a more atherogenic profile of the different markers analyzed in comparison with mice with a 414 
normal Ogg1 gene expression. In the Ogg1 (-/-) mice, higher serum IL-1β and IL-18 levels, 415 
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higher oxidized mitochondrial DNA and higher inflammasome activation were detected. Taking 416 
into account that OGG1 is the major DNA glycosylase responsible for removing the most 417 
abundant products of oxidative DNA damage, it is not surprising to find a pro-atherosclerotic 418 
phenotype in mice deficient in the ogg1 gene. Interestingly, these authors also reported higher 419 
levels of triglycerides in deficient mice
32
. Interestingly, in PREDIMED participants, higher 420 
plasma triglycerides in Cys326Cys participants were also detected. Overall, OGG1 may play a 421 
protective role in atherogenesis by preventing excessive inflammasome activation
32
. In humans, 422 
most of the few studies carried out on cardiovascular disease
33-35,54
 also have found a higher risk 423 
associated with the Cys326 allele. Thus, Izzoti et al
33
 examined the survival of patients with 424 
severe atherosclerosis and concluded that those bearing the OGG1 homozygous slow 425 
polymorphism had increased levels of two bulky DNA adducts, being more susceptible than 426 
other individuals to the genotoxic consequences of oxidative stress in the arterial wall. Orhan et 427 
al
35
 also concluded that the OGG1-rs1052133 played a role in stroke risk, and Shyu et al
34
 428 
reported an effect of smoking increasing stroke risk in Chinese carriers of the Cys allele. The 429 
present study results showing a strong association between the OGG1-rs1052133 polymorphism 430 
and cardiovascular mortality in Cys326Cys homozygotes concur with these findings. Because a 431 
high cardiovascular risk population was analyzed, it is no surprise that the association of the 432 
OGG1-rs1052133 polymorphism was stronger for cardiovascular disease mortality than cancer 433 
mortality. 434 
Of note, cardiovascular mortality is also gaining in importance in cancer patients
61,62
, as 435 
their increased survival allows them to reach older ages in which their risk of death may be 436 
determined by cardiovascular risk factors. For instance, in a population-based cohort study 437 
conducted among 98,999 women diagnosed with early-stage breast cancer, those 66 years or 438 
older who survived 5 years or more after diagnosis had cardiovascular disease as the leading 439 
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cause of death, exceeding breast cancer mortality rates at 10 years after diagnosis
62
. 440 
 Age is an important determinant of mortality. The mean age of the deceased due to cancer 441 
in the PREDIMED cohort was significantly lower than the mean age of the deceased due to 442 
cardiovascular diseases. Interestingly, it was found that, in the younger age group (<66.5 years), 443 
the OGG1-rs1052133 polymorphism was indeed more associated with cancer mortality than 444 
cardiovascular mortality. Conversely, the association of the OGG1 polymorphism with higher 445 
cardiovascular mortality was mainly detected in the older age group. This may be explained by 446 
the age-dependent reduction of the DNA repair efficiency, enhanced in Cys326Cys participants
2
. 447 
In younger participants, the increased cancer mortality associated with this polymorphism may be 448 
associated with an additional genetic component related to specific locations (i.e. BRCA1, 449 
BRCA2, etc.) in which the OGG1-risk genotype may contribute to enhance the genome 450 
instability that increases the risk, being also considered as a cancer risk modifier
63
. 451 
When analyzing gene-diet interactions, sample size limitations due to the recessive effect 452 
and the relatively low prevalence of the Cys326Cys genotype in this population (4.2%) prevented 453 
examination of the dietary modulation of the effects of the OGG1-rs1052133 polymorphism on 454 
cancer mortality (only 6 deaths with the Cys326Cys genotype were detected). Related to this, it is 455 
known that the prevalence of the OGG1-rs1052133 polymorphism is lower in white (1.8-8.6 per 456 
cent Cys326Cys participants) than in Asian populations (13.4-38.2 per cent Cys326Cys)
64
. 457 
However, bearing this limitation in mind, it was possible to explore dietary modulation in 458 
determining all-cause mortality and cardiovascular mortality (involving more homozygotes). 459 
When testing whether intervention with the MedDiet modulated the effect of the Cys326Cys 460 
genotype increasing total mortality a statistically significant interaction was not found. Likewise, 461 
for cardiovascular mortality in the whole population, the interaction term between the OGG1 462 
genotype and MedDiet did not reach statistical significance. Further studies are needed to provide 463 
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further evidence on the modulation of the MedDiet intervention on the effects of the OGG1-464 
rs1052133 polymorphism on mortality risk. 465 
The MedDiet is characterized by a high intake of vegetables
37,65
. Vegetables are very rich 466 
in antioxidants and other phytochemicals
66,67 
that may contribute to a better DNA protection from 467 
oxidation in Cys326Cys individuals who have less capacity for repairing it
68-70
. Recent meta-468 
analyses
71,72 
have shown that high vegetable consumption is associated with a lower risk of all-469 
cause mortality
71,72
, particularly cardiovascular mortality
72
. Although no previous study has 470 
analyzed the interaction between vegetable consumption and the OGG1-rs1052133 471 
polymorphism in determining total or cause-specific mortality, this gene-diet interaction on 472 
cancer risk has been analyzed in some reports
28,73,74
. Noteworthy is the work of Sorensen et al
28
, 473 
showing a statistically significant interaction between vegetable intake and the OGG1-rs1052133 474 
polymorphism on lung cancer incidence, with a 54% decrease in cancer risk per 50% increase in 475 
vegetable consumption among Cys326Cys participants and no decrease in risk among Ser326Ser 476 
or Ser326Cys individuals. In the PREDIMED study, a similar interaction between theOGG1-477 
rs1052133 polymorphism and vegetable intake in determining cardiovascular mortality in the 478 
whole population has been detected, in such a way that a high vegetable intake was associated 479 
with a greater reduction of cardiovascular mortality in Cys326Cys homozygotes in comparison 480 
with Ser-carriers. This effect had a similar trend for total mortality but only reached significance 481 
in the older age group. 482 
CONCLUSIONS  483 
In conclusion, in a Mediterranean population at high cardiovascular disease risk, an association of 484 
the OGG1-rs1052133 polymorphism with higher total and cardiovascular mortality in 485 
Cys326Cys homozygotes has been found, while higher cancer mortality was only detected in the 486 
lower age group. Recessive effects limited the study of gene-diet interactions. Non-significant 487 
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interaction terms were detected for the MedDiet intervention. Nevertheless, a significant gene-488 
diet interaction with vegetable consumption in determining cardiovascular mortality has been 489 
observed, in such a way that higher consumption decreased the risk more in Cys326Cys 490 
participants, supporting the beneficial role of the antioxidant compounds present in vegetables in 491 
providing protection from DNA damage and mortality risk in genetically susceptible individuals. 492 
However, replication of these results in other studies is needed to confirm these associations and 493 
dietary modulations. 494 
  495 
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LEGEND TO FIGURE 
Figure 1: Cumulative mortality-free survival by the OGG1-rs1052133 (Ser326Cys) 
polymorphism for total mortality in the whole population (A), cardiovascular mortality in the 
whole population (B), cancer mortality in the whole population (C) and cancer mortality in 
participants aged less than 66.5 years (D). Kaplan-Meier curves were depicted for the three 
genotypes, the one letter code was used for the amino acids (S indicated serine and C indicates 
cysteine) (n = 4519 SS, n = 2349 SC and n = 302 SS in the whole population). In the group of 
participants aged less than 66.5 years, n=3515 individuals. Multivariable Cox regression models 
were used to estimate the hazard ratios (HR) and 95% confidence intervals (CI). Models were 
adjusted for age, sex, field center, dietary intervention group, type-2 diabetes, BMI, self-reported 
personal history of a previously diagnosed cancer at baseline, alcohol consumption, smoking, 
physical activity, hypertension, dyslipidemia, medications (lipid-lowering, hypoglycemic, and 
antihypertensive drugs) and adherence to the Mediterranean Diet. P
1
 indicates the P-value for the 
comparison between CC and CS genotypes in the multivariable Cox regression model. HR and 
CI were estimated in the corresponding multivariable Cox regression models for CC participants 
in comparison with SS (P
2
) or in comparison with SS and SC grouped together (recessive model) 
(P
3
) for each cause of death. 
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Figure 1
 Table 1: Demographic, clinical, lifestyle and genetic characteristics of the 
PREDIMED study participants at baseline according to the OGG1-rs1052133 
genotype (n = 7,170)
a
 
        
  
Ser326Ser 
(n=4,519) 
Ser326Cys 
(n=2,349) 
Cys326Cys 
(n=302) P
b
 
Age (years) 66.9 (6.2) 67.0 (6.2) 67.3 (6.2) 0.526 
BMI (kg/m
2
)
c
 29.9 (3.9) 30.1 (3.8) 29.5 (3.7) 0.016 
Female sex : n, % 2601 (57.6) 1346 (57.3) 171 (56.6) 0.939 
Current smokers: n, % 661 (14.6) 300 (12.8) 41 (13.6) 0.204 
Type 2 diabetes: n, % 2195 (48.6) 1127 (48.0) 142 (47.0) 0.807 
Hypertension: n, % 3729 (82.5) 1959 (83.4) 248 (82.1) 0.626 
Dyslipidemia: n, % 3259 (72.1) 1707 (72.7) 225 (74.5) 0.627 
OGG1-rs1052133: n, % 
      
0.069 
MedDiet with EVOO
d
 1550 (62.7) 817 (33.0) 106 (4.3) 
 
MedDiet with Nuts 1525 (64.5) 729 (32.6) 110 (4.7) 
 
Control group 1444 (61.9) 803 (34.4) 86 (3.7) 
 
SBP (mm Hg)
e
 149.3 (20.5) 149.5 (21.3) 148.1 (20.1) 0.543 
DBP (mm Hg)
f
 83.3 (11.0) 83.4 (11.0) 83.9 (11.2) 0.676 
Total cholesterol (mg/dL)
g
 210.4 (38.4) 210.7 (37.8) 208.6 (38.3) 0.697 
LDL-C (mg/dL)
g,h
 129.4 (33.8) 130.4 (33.4) 125.9 (34.1) 0.083 
HDL-C (mg/dL)
g,i
 53.9 (14.1) 53.7 (13.4) 53.4 (14.5) 0.762 
Triglycerides (mg/dL)
j
 136.7 (74.9) 135.1 (70.9) 149.6 (89.7) 0.018 
Fasting glucose (mg/dL)
k
 121.9 (40.5) 122.5 (41.7) 122.6 (46.1) 0.838 
Energy intake (kcal/d) 2273 (598) 2275 (614) 2321 (647) 0.411 
Total fat (g/d) 98.6 (30.1) 98.7 (30.7) 100.6 (30.9) 0.554 
Saturated fat (g/d) 25.2 (9.1) 25.4 (9.2) 25.8 (10.1) 0.368 
MUFA (g/d)
l
 48.9 (16.0) 48.7 (16.1) 49.8 (15.2) 0.530 
PUFA (g/d)
m
 15.8 (7.0) 15.9 (7.1) 16.2 (6.9) 0.663 
Protein (g/d) 92.2 (22.9) 93.0 (23.4) 94.9 (25.0) 0.087 
Carbohydrate (g/d) 239.4 (79.9) 238.8 (82.5) 245.6 (87.0) 0.395 
Fat (% energy) 39.2 (6.8) 39.2 (6.8) 39.2 (6.8) 0.554 
Carbohydrate (% energy) 41.9 (7.2) 41.7 (7.1) 42.0 (7.0) 0.395 
Protein (% energy) 92.2 (22.9) 93.0 (23.4) 94.9 (25.0) 0.087 
Fiber (g/d) 25.6 (9.0) 25.7 (9.4) 26.0 (8.9) 0.604 
Table 1
Vegetable (g/d) 334.9 (146.4) 340.9 (156.8) 339.8 (151.0) 0.281 
Fruit (g/d) 371.2 (206.2) 373.2 (210.3) 364.7 (192.1) 0.780 
Meat (g/d) 131.8 (60.0) 133.1 (58.4) 139.7 (62.7) 0.075 
Olive oil (g/d) 39.5 (17.9) 38.8 (18.2) 40.2 (16.7) 0.266 
Adherence to the MedDiet (points)
n
 8.6 (2.0) 8.6 (1.9) 8.7 (1.9) 0.969 
Alcohol consumption (g/d) 8.4 (14.2) 8.5 (14.4) 7.7 (13.0) 0.685 
Physical activity (MET-min/day)
o
 233 (239) 230 (243) 228 (225) 0.904 
  
a: Values are mean(SD) for continuous variables and number (%) for categorical variables. Food intake, total energy and 
macronutrients were available in 7,122 participants. Biochemical determinations were available for almost 7,000 participants (from 
6,767 for LDL-C to 6,903 for Total cholesterol). 
b: P unadjusted. 
c: BMI: body mass index; 
d: EVOO: extra virgin olive oil; 
e: SBP: Systolic blood pressure, 
f: DBP: Diastolic blood pressure; 
g: Cholesterol conversion units: 1 mg/dL = (1/38.610039) mmol/L; 
h: LDL-C: Low-Density Lipoprotein Cholesterol; 
i: HDL-C: High-Density Lipoprotein Cholesterol; 
j: Triglycerides conversion units: 1 mg/dL = (1/88.495575) mmol/L; 
k: Glucose conversion units: 1 mg/dL = (1/18.018018) mmol/L; 
l: MUFA: Monounsaturated fatty acids; 
m: PUFA: Polyunsaturated fatty acids; 
n: MedDiet: Mediterranean diet; Adherence to the MedDiet (ADM) score based on a 14-point screener of adherence: a higher score 
represents greater ADM38; 
o: MET: metabolic equivalent of physical activity in leisure time; 
 
 
 
 
 Table 2: Baseline characteristics at the time of entry and future cause of death after 4.8 years of 
median follow-up of the PREDIMED study participants by vital status
a
 
              
  
Alive 
(n=6,852) 
Cancer 
(n=127) 
CVD
b
 
(n=81) 
Other 
(n=110) P
c
 
 
Total deaths 
(n=318) P
d
 
Age (years) 66.8 (6.1) 68.2 (6.0) 71.8 (6.4) 71.4 (6.6) < 0.001 
 
70.6 (6.4) < 0.001 
BMI (kg/m
2
)
e
 30.0 (3.8) 29.8 (3.9) 29.9 (4.2) 29.2 (4.3) 0.202 
 
30.0 (3.8) 0.101 
SBP (mm Hg)
f
 149.2 (20.7) 152.5 (20.5) 156.9 (22.1) 149.6 (22.6) 0.003 
 
152.8 (21.9) 0.003 
DBP (mm Hg)
g
 83.4 (11.0) 83.2 (11.0) 82.9 (11.5) 82.8 (11.5) 0.915 
 
83.1 (11.4) 0.629 
Energy intake (kcal/d) 2273 (602) 2309 (636) 2423 (699) 2269 (700) 0.154 
 
2323 (675) 0.161 
Total fat (% energy) 39.2 (6.8) 38.1 (6.7) 39.2 (6.5) 39.9 (7.7) 0.270 
 
39.0 (7.1) 0.754 
Saturated fat (% energy) 10.0 (2.2) 9.8 (2.4) 10.6 (2.4) 10.5 (2.3) 0.003 
 
10.3 (2.4) 0.023 
MUFA (% energy)
h
 19.5 (4.5) 19.0 (4.2) 18.9 (4.5) 20.1 (5.7) 0.199 
 
19.3 (4.8) 0.613 
PUFA (% energy)
i
 6.2 (2.1) 6.1 (2.2) 6.0 (2.4) 6.2 (2.0) 0.567 
 
6.1 (2.2) 0.186 
Protein (% energy) 16.6 (2.8) 16.3 (2.9) 16.3 (3.2) 16.7 (3.4) 0.486 
 
16.5 (3.2) 0.437 
Carbohydrate (% energy) 41.9 (7.1) 42.1 (7.0) 41.3 (7.2) 41.3 (7.7) 0.766 
 
41.6 (7.3) 0.465 
ADM (points)
j
 8.7 (2.0) 8.5 (1.9) 8.1 (2.0) 8.5 (2.0) 0.068 
 
8.4 (2.0) 0.029 
Sex : n, % 
        
< 0.001 
   
< 0.001 
Male : n, % 2857 (93.6) 77 (2.5) 52 (1.7) 66 (2.2) 
  
195 (6.4) 
 Female : n, % 3996 (97.0) 50 (1.2) 29 (1.0) 43 (1.0) 
  
123 (3.0) 
 History of cancer: n, % 
        
< 0.001 
   
< 0.001 
Yes : n, % 184 (88.9) 17 (8.2) 2 (1.0) 4 (1.9) 
  
23 (11.1) 
 No : n, % 6668 (95.8) 110 (1.6) 79 (1.1) 105 (1.5) 
  
295 (4.2) 
 
Type 2 diabetes: n, % 
        
< 0.001 
   
< 0.001 
Yes : n, % 3269 (94.4) 68 (2.0) 52 (1.5) 75 (2.2) 
  
196 (5.7) 
 No : n, % 3584 (96.7) 59 (1.6) 29 (0.8) 34 (0.9) 
  
122 (3.3) 
 OGG1-rs1052133: n, % 
        
0.003 
   
0.016 
Ser326Ser 4318 (95.6) 81 (1.8) 50 (1.1) 70 (1.5) 
  
201 (4.4) 
 Ser326Cys 2256 (96.0) 40 (1.7) 20 (0.9) 34 (1.4) 
  
94 (4.0) 
 Cys326Cys 279 (92.4) 6 (2.0) 11 (3.6) 6 (2.0) 
  
23 (7.6) 
 OGG1-rs1052133: n, % 
        
< 0.001 
   
0.006 
Ser-carrier 6574 (95.7) 121 (1.8) 70 (1.0) 104 (1.5) 
  
295 (4.3) 
 Cys326Cys 279 (92.4) 6 (2.0) 11 (3.6) 6 (2.0)     23 (7.6)   
a: Values are mean(SD) for continuous variables and number (%) for categorical variables; 
b: CVD: Cardiovascular diseases; 
c: Unadjusted P-value for the comparison among the 4 groups; 
d: Unadjusted P-value for the comparison between total deaths and alive; 
e: BMI: body mass index; 
f: SBP: Systolic blood pressure, 
g: DBP: Diastolic blood pressure; 
h: MUFA: Monounsaturated fatty acids; 
i: PUFA: Polyunsaturated fatty acids; 
j: MedDiet: Mediterranean diet; Adherence to the MedDiet (ADM) score based on a 14-point screener of adherence: a higher score represents greater ADM38. 
 
Table 2
 Table 3. Mortality rate and hazard ratios (HR) for total mortality and cause-specific mortality (cancer 
and cardiovascular) in the PREDIMED participants depending on the OGG1-rs1052133 polymorphism, 
after 4.8 years of median follow-up 
            
 
Whole population (n = 7,170) 
   
Model 1
a
 Model 2
b
 Model 3
c
 
OGG1-rs1052133 
genotypes 
Deaths / 
person-y 
Mortality 
rate
d
 HR 95% CI P HR 95% CI P HR 95% CI P 
Total mortality (deaths: 318) 
         
Codominant model 
          
Ser326Ser 201/19502 10.3 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Ser326Cys 94/10085 9.3 0.89 (0.70-1.14) 0.356 0.88 (0.68-1.12) 0.285 0.87 (0.68-1.03) 0.275 
Cys326Cys 23/1302 17.7 1.70 (1.10-2.63) 0.016 1.70 (1.10-2.61) 0.017 1.61 (1.03-2.51) 0.036 
Recessive model 
          
Ser-carriers 295/29587 10.0 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 23/1302 17.7 1.77 (1.16-2.71) 0.009 1.77 (1.16-2.71) 0.009 1.69 (1.09-2.62) 0.018 
Cancer mortality (deaths: 127) 
         
Recessive model 
          
Ser-carriers 121/29587 4.1 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 6/1302 4.6 1.13 (0.50-2.57) 0.771 1.12 (0.49-2.53) 0.796 1.07 (0.47-2.45) 0.867 
Cardiovascular mortality (deaths: 81) 
         
Recessive model 
          
Ser-carriers 70/29587 2.4 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 11/1302 8.4 3.87 (2.03-7.36) < 0.001 3.86 (2.02-7.35) < 0.001 3.31 (1.68-6.53) 0.001 
a: Model 1: Adjusted for sex, age, center and dietary intervention group. 
b: Model 2: Adjusted for variables in model 1 plus body mass index, type-2 diabetes and self-reported cancer history at baseline. 
c: Model 3: Adjusted for variables in model 2 plus drinking, smoking, physical activity, adherence to Mediterranean diet and medications (hypertension, dyslipemia and 
type-2 diabetes) at baseline. 
d: Mortality rates were expressed per 1000 person-years of follow-up. 
 
Table 3
 Table 4. Mortality rate and hazard ratios (HR) for total mortality and cause-specific mortality (cancer and 
cardiovascular) in the PREDIMED participants depending on the OGG1-rs1052133 polymorphism, after 
4.8 years of median follow-up. Stratified analysis by age group
a
 
            
   
Model 1
b
 Model 2
c
 Model 3
d
 
OGG1-rs1052133 
genotypes 
Deaths / 
person-
years 
Mortality 
rate
e
 HR 95% CI P HR 95% CI P HR 95% CI P 
Total mortality (deaths: 318) 
         
            
Age group < 66.5 years (n = 3515) 
         
Ser-carriers 80/14402 5.6 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 7/584 12.0 2.27 (1.04-4.95) 0.039 2.33 (1.07-5.08) 0.034 2.63 (1.19-5.83) 0.017 
Age group ≥ 66.5 years (n = 3655) 
         
Ser-carriers 215/15216 14.1 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 16/719 22.3 1.67 (1.00-2.78) 0.051 1.67 (1.00-2.78) 0.051 1.62 (0.95-2.75) 0.077 
P (interaction OGG1 x Age group)
f
 
  
0.627 
  
0.570 
  
0.570 
Cancer mortality (deaths: 127) 
         
            
Age group < 66.5 years (n = 3515) 
         
Ser-carriers 37/14402 2.6 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 4/584 6.8 2.77 (0.98-7.84) 0.055 3.00 (1.05-8.54) 0.040 3.27 (1.13-9.47) 0.029 
Age group ≥ 66.5 years (n = 3655) 
         
Ser-carriers 84/15216 5.5 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 2/719 2.8 0.52 (0.13-2.14) 0.360 0.50 (0.12-2.04) 0.333 0.46 (0.11-1.90) 0.285 
P (interaction OGG1 x Age group)
f
 
  
0.063 
  
0.047 
  
0.048 
Cardiovascular mortality (deaths: 81) 
         
            
Age group < 66.5 years (n = 3515) 
         
Ser-carriers 19/14402 1.3 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 1/584 1.7 1.37 (0.19-10.36) 0.761 1.40 (0.19-10.60) 0.744 1.88 (0.23-15.20) 0.555 
Age group ≥ 66.5 years (n = 3655) 
                     
Ser-carriers 51/15216 3.4 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 10/719 13.9 4.89 (2.43-9.78) <0.001 5.00 (2.48-10.01) 
<
0.001 4.60 (2.18-9.71) <0.001 
P (interaction OGG1 x Age group)
f
 
  
0.219 
  
0.212 
  
0.234 
a: Age groups were considered taking into account the median of age at baseline. 
b: Model 1: Adjusted for sex, age, center and dietary intervention group. 
c: Model 2: Adjusted for variables in model 1 plus body mass index, type-2 diabetes and self-reported cancer history at baseline. 
d: Model 3: Adjusted for variables in model 2 plus drinking, smoking, physical activity, adherence to Mediterranean diet and medications (hypertension, dyslipemia and 
type-2 diabetes) at baseline. 
Table 4
e: Mortality rates were expressed per 1000 person-years of follow-up. 
f: P-values obtained for multiplicative interaction terms in the corresponding multivariable-adjusted Cox regression model. 
 
 Table 5. Mortality rate and hazard ratios (HR) for total mortality and cardiovascular mortality in the 
PREDIMED participants according to the OGG1-rs1052133 polymorphism, after 4.8 years of median follow-
up, depending on the Mediterranean diet intervention
a
 
            
 
Whole population (n = 7,170) 
   
Model 1
b
 Model 2
c
 Model 3
d
 
OGG1-rs1052133 
genotypes 
Deaths / 
person-
years 
Mortality 
rate
e
 HR 95% CI P HR 95% CI P HR 95% CI P 
Total mortality (deaths: 318) 
         
            
Mediterranean diet (n = 4837) 
         
Ser-carriers 202/20655 9.8 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 16/952 16.8 1.61 (0.97-2.69) 0.068 1.66 (0.99-2.76) 0.071 1.61 (0.96-2.69) 0.070 
Control group (n = 2333) 
         
Ser-carriers 93/8963 10.4 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 7/349 20.0 2.09 (0.97-4.54) 0.061 2.04 (0.94-4.43) 0.071 2.14 (0.98-4.65) 0.056 
P (interaction OGG1 x Intervention group)
f
 
 
0.469 
  
0.558 
  
0.752 
Cardiovascular mortality (deaths: 81) 
         
            
Mediterranean diet (n = 4837) 
         
Ser-carriers 45/20655 2.2 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 6/952 6.3 2.73 (1.16-6.48) 0.020 2.78 (1.17-6.60) 0.020 2.60 (1.07-6.22) 0.034 
Control group (n = 2333) 
         
Ser-carriers 25/8963 2.8 1.00  (ref.) 
 
1.00  (ref.) 
 
1.00  (ref.) 
 
Cys326Cys 5/349 14.3 7.48 (2.77-20.16) <0.001 8.16 (3.00-22.20) <0.001 7.89 (2.48-25.11) <0.001 
P (interaction OGG1 x Intervention group)
f
 
 
0.181 
  
0.167 
  
0.200 
a: Both, Mediterranean diet intervention groups, were analyzed together. 
b: Model 1: Adjusted for sex, age, center and dietary intervention group. 
c: Model 2: Adjusted for variables in model 1 plus body mass index, type-2 diabetes and self-reported cancer history at baseline. 
d: Model 3: Adjusted for variables in model 2 plus drinking, smoking, physical activity, adherence to Mediterranean diet, medications (hypertension, dyslipemia and type-2 
diabetes) and total energy intake at baseline. Energy intake data in Model 3 were only available in 7,122 participants. 
e: Mortality rates were expressed per 1000 person-years of follow-up. 
f: P-values obtained for multiplicative interaction terms in the corresponding multivariable-adjusted Cox regression model. 
 
Table 5
 Table 6. Mortality rate and hazard ratios (HR) for total mortality and cardiovascular mortality in the 
PREDIMED participants according to the OGG1-rs1052133 polymorphism, after 4.8 years of median 
follow-up, depending on vegetable intake
a
 
            
 
Whole population (n = 7,122) 
   
Model 1
b
 Model 2
c
 Model 3
d
 
OGG1-rs1052133 
genotypes 
Deaths / 
person-
years 
Mortality 
rate
e
 HR 95% CI P HR 95% CI P HR 95% CI P 
Total mortality (deaths: 313) 
         
            
Vegetable intake (2 groups) 
         Low intake (< 314 g/d) (n = 3532) 
         
Ser-carriers 165/14910 11.1 1.00 (ref.) 
 
1.00 (ref.) 
 
1.00 (ref.) 
 
Cys326Cys 14/650 21.5 2.01 (1.16-3.49) 0.013 1.97 (1.14-3.41) 0.016 1.92 (1.16-3.36) 0.022 
High intake (>=314 g/d) (n = 3580) 
        
Ser-carriers 126/14517 8.7 1.00 (ref.) 
 
1.00 (ref.) 
 
1.00 (ref.) 
 
Cys326Cys 8/639 12.5 1.36 (0.66-2.79) 0.407 1.43 (0.69-2.93) 0.333 1.37 (0.66-2.81) 0.395 
P (interaction OGG1 x Vegetable intake)
f
 
 
0.446 
  
0.444 
  
0.491 
Vegetable intake (as continuous) 
         
Interaction term OGG1 x Vegetables
g
 0.75 (0.45-1.25) 0.268 0.79 (0.48-1.30) 0.360 0.80 (0.49-1.30) 0.367 
Cardiovascular mortality (deaths: 80) 
         
            
Vegetable intake (2 groups) 
         
Low intake (< 314 g/d) (n = 3532) 
         
Ser-carriers 39/14910 2.6 1.00 (ref.) 
 
1.00 (ref.) 
 
1.00 (ref.) 
 
Cys326Cys 8/650 12.3 5.23 (2.40-11.38) <0.001 5.15 (2.36-11.24) <0.001 5.21 (2.36-11.52) <0.001 
High intake (>=314 g/d) (n = 3580) 
        
Ser-carriers 31/14517 2.1 1.00 (ref.) 
 
1.00 (ref.) 
 
1.00 (ref.) 
 
Cys326Cys 2/639 3.1 1.18 (0.28-5.05) 0.823 1.26 (0.29-5.40) 0.757 1.38 (0.31-6.19) 0.671 
P (interaction OGG1 x Vegetable intake)
f
 
 
0.096 
  
0.120 
  
0.101 
Vegetable intake (as continuous) 
         
Interaction term OGG1 x Vegetables
g
 0.37 (0.15-0.93) 0.035 0.38 (0.15-0.96) 0.041 0.42 (0.18-0.98) 0.046 
a: Vegetable intake were analyzed as categorical (2 groups based on the median population intake) and as continuous variable (g/d). This variable was standardized and HRs 
were expressed per 1 standard deviation (approx. 150 g/d). Vegetable intake data were only available in 7,122 participants. In PREDIMED, one average serving of 
vegetables was estimated in 125 g/d. Then, 314 g/d of vegetables are equivalent to 2.5 servings/d. 
b: Model 1: Adjusted for sex, age, center and dietary intervention group. 
c: Model 2: Adjusted for variables in model 1 plus body mass index, type-2 diabetes and self-reported cancer history at baseline. 
d: Model 3: Adjusted for variables in model 2 plus drinking, smoking, physical activity, adherence to Mediterranean diet, medications (hypertension, dyslipemia and type-2 
diabetes) and total energy intake at baseline. 
Table 6
e: Mortality rates were expressed per 1000 person-years of follow-up. 
f: P-values obtained for multiplicative interaction terms between the OGG1 genotype and vegetable intake, as categorical, in the corresponding multivariable-adjusted Cox 
regression model. 
g: HR 95% confidence interval and P-value for multiplicative interaction terms, between the OGG1 genotype and vegetable intake (as continuous), in the corresponding 
multivariable-adjusted Cox regression model. HRs are expressed per 1 standard deviation increase in vegetable intake. 
 
 
 
